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We thank Umans and Lindheimer for their interest in our meeting summary (1) and 
welcome the opportunity to respond to their concerns. We agree with the authors about the 
need for more data to inform various aspects of medication treatment during pregnancy; this 
was evident to all the subject matter experts who attended the CDC meeting and is likely 
appreciated by the journal’s readership.
The agencies represented at the meeting have continued their efforts to address the current 
data gap. In an attempt to raise greater awareness among policy makers and the general 
public about safer medication use in pregnancy as a pressing public health issue, CDC 
posted an infographic on the Treating for Two website, available at http://www.cdc.gov/
pregnancy/meds/treatingfortwo/infographic.html. While this infographic focuses on the lack 
of medication safety data, CDC continues with its commitment to conduct research on the 
safety of medications in pregnant women. In addition, as mentioned by the authors, our 
NICHD (National Institute of Child Health and Human Development) colleagues have 
documented the parallel alarming dearth of pharmacokinetic/pharmacodynamic data during 
pregnancy, and continue to do important work in this area. (2) FDA continues its efforts to 
consider ways to collect safety data in pregnant women, as was demonstrated by the May 
2014 public meeting held at the FDA, “Study Approaches and Methods to Evaluate the 
Safety of Drugs and Biological Products during Pregnancy in the Post-Approval Setting”. 
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(3) Draft guidance on the scientific and ethical considerations for the inclusion of pregnant 
women in clinical trials is also being developed by FDA. In regards to the final rule on 
Pregnancy and Lactation Labeling, the rulemaking process is complex, including several 
layers of review. We are happy to note that the rule published on December 4, 2014 and will 
be fully in effect on June 30, 2015 (http://www.fda.gov/Drugs/
DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm).
Healthcare providers and regulators have to make decisions now with whatever data and 
guidance are currently available. While further research on both safety and efficacy of 
medication use in pregnancy is obviously needed, the intent of the expert meeting and 
resulting summary publication was to focus on how to collaboratively move forward and 
utilize the decades of research that have accumulated thus far to provide better information 
to improve decision-making. We need to continue to gather data, and develop evidence-
based guidance, for better informed decisions, ultimately leading to healthier pregnancies 
and healthier babies.
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